Subscribe To Thriver News

Get our weekly updates

Douglas_Dieterich_CROI_1000The hepatitis C protease inhibitor faldaprevir added to pegylated interferon and ribavirin cured hepatitis C in nearly three-quarters of people with genotype 1 hepatitis C virus (HCV) and HIV co-infection in the STARTVerso4 trial, equaling response rates for people with hepatitis C alone, according to a report at the 21st Conference on Retroviruses and Opportunistic Infections (CROI) this week in Boston.

Direct-acting antivirals have revolutionized treatment for chronic hepatitis C. These drugs were initially tested as add-ons to the previous standard of care, pegylated interferon plus ribavirin. Although interferon-free combinations are now becoming available, regimens containing single direct-acting drugs plus interferon may remain an option for some patients.

See the rest of the article HERE


Leave a Reply

Your email address will not be published.